Acorda Therapeutics (ACOR) Tops Q3 EPS by 16c

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.31, $0.16 better than the analyst estimate of $0.15. Revenue for the quarter came in at $148.2 million versus the consensus estimate of $115.52 million.

"AMPYRA continued to grow robustly in the third quarter, supporting our ongoing investment in an exciting late stage pipeline, while the Company remained cash flow positive. Our top priority is the successful development of our clinical pipeline,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We expect several data milestones in 2016 for our most advanced programs, led by CVT-301 for the treatment of off episodes in Parkinson’s disease, PLUMIAZ for seizure clusters in epilepsy and dalfampridine for the treatment of post-stroke walking deficits.”

“We were also encouraged by positive developments in defending our intellectual property around AMPYRA. Our legal team has been recognized nationally for its achievements in the area of patent litigation.”

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Unifi, Inc. (UFI) Misses Q4 EPS by 11c
• Accuray (ARAY) Tops Q4 EPS by 1c